Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBurford Capital Regulatory News (BUR)

Share Price Information for Burford Capital (BUR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,077.00
Bid: 1,092.00
Ask: 1,093.00
Change: -26.00 (-2.36%)
Spread: 1.00 (0.092%)
Open: 1,160.00
High: 1,160.00
Low: 1,077.00
Prev. Close: 1,103.00
BUR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: Burford Capital (BUR): Next $1.6bn of investments to boost returns

3 Jan 2019 10:30

Hardman & Co Research Hardman & Co Research: Burford Capital (BUR): Next $1.6bn of investments to boost returns 03-Jan-2019 / 10:30 GMT/BST


Hardman & Co Research: Next $1.6bn of investments to boost returns

Burford has announced access to almost $1bn of new capital, which, combined with its balance sheet, gives a new and financially attractive structure for how the next $1.6bn of litigation finance investments will be made. The most significant part of this is a new strategic capital relationship with a sovereign wealth fund (SWF). The SWF and Burford have committed a $1bn pool of capital, with the former supplying $667m. Burford will supply the remaining one-third of the capital, but receive 60% of the investment profits. In addition, 50% of the new investments made will be allocated to the pool over the next four years, or until the pool is invested.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/next-1-6bn-of-investments-to-boost-returns/

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.comFollow us on Twitter @HardmanandCo Contact: Dr Brian Moretta +44 20 7194 7622 bm@hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

763163 03-Jan-2019 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
26th Jun 20236:00 pmRNSDirector/PDMR Shareholding
26th Jun 20232:08 pmRNSUpdate & Release Date for 2Q23 Results
26th Jun 20232:07 pmRNSNotice of Early Redemption of Bonds due 2024
26th Jun 20232:05 pmRNSClosing of Private Offering of Senior Notes
23rd Jun 20237:00 amRNSPricing of Senior Notes Offering
22nd Jun 20235:22 pmRNSDirector/PDMR Shareholding
20th Jun 20231:00 pmRNSPrivate Offering of Senior Notes
13th Jun 202312:00 pmRNS1Q23 Results & Quarterly Report
8th Jun 20233:00 pmRNSNotice of 1Q23 Results & Results Call Details
6th Jun 202312:00 pmRNSNotice of Retail Shareholder Call on June 21, 2023
6th Jun 202312:00 pmRNSNotice of 2023 AGM
2nd Jun 202312:00 pmRNSSterling FX Rate for Second 2022 Interim Dividend
16th May 202312:00 pmRNSAvailability of 2022 Annual Report
16th May 202312:00 pmRNSAnnual results for year ended December 31, 2022
3rd May 20237:00 amRNSNotice of 2022 Results and Update on Accounting
3rd Apr 20237:30 amRNSRestoration - Burford Capital Limited
3rd Apr 20237:00 amRNSStatement on YPF Summary Judgment Ruling
31st Mar 20234:57 pmRNSSuspension - Burford Capital Limited
31st Mar 20234:14 pmRNSStatement re Petersen and Eton Park Matters
29th Mar 20233:00 pmRNSTransaction in Own Shares
22nd Mar 20234:00 pmRNSDirector/PDMR Shareholding
16th Mar 20237:00 amRNSUpdate on 2022 Business Activity
3rd Jan 202312:00 pmRNSUpdate on and Completion of Share Purchases by EBT
30th Dec 20221:13 pmRNSDirector/PDMR Shareholding
28th Dec 202212:00 pmRNSUpdate on Share Purchases by EBT
16th Dec 202212:00 pmRNSUpdate on Share Purchases by EBT
9th Dec 20225:00 pmRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSIntended Share Purchases by Employee Benefit Trust
25th Nov 202212:00 pmRNSDirector/PDMR Bondholding
16th Nov 202212:00 pmRNSAppointment of Joint Corporate Broker
9th Nov 202212:00 pmRNSSterling FX Rate for 2022 Interim Dividend
1st Nov 20221:23 pmRNSBurford Capital Releases 2022 GC Survey Results
13th Sep 20223:27 pmRNSBurford Capital-Report on Class Action Recoveries
6th Sep 20227:00 amRNSJordan Licht Appointed Chief Financial Officer
26th Aug 20222:00 pmRNSDirector/PDMR Shareholding
24th Aug 20222:00 pmRNSDirector/PDMR Shareholding
16th Aug 20222:00 pmRNSPDMR Shareholding and Transaction in Own Shares
9th Aug 202212:01 pmRNSDr. Rukia Baruti Appointed as Board Director
9th Aug 202212:00 pmRNSInterim Results for six months ended 30 June 2022
26th Jul 20222:00 pmRNSTR-1: Notification of Major Holdings
26th Jul 202212:00 pmRNSNotice of 1H22 Results Date & Results Call Details
25th Jul 20222:00 pmRNSTR-1: Notification of Major Holdings
27th Jun 202211:30 amRNSDirector/PDMR Shareholding
15th Jun 20225:30 pmRNSPurchases of Shares for NED Plan and PDMR Notices
13th Jun 20227:00 amRNS$350 Million Post-Settlement Investment Fund Close
10th Jun 20223:00 pmRNSIntended Purchases of Ordinary Shares
7th Jun 20223:00 pmRNSNotification of Major Holdings
1st Jun 20223:00 pmRNSRetail Shareholder Call Registration Details
1st Jun 202210:00 amRNSSterling FX Rate for 2021 Final Dividend
26th May 202212:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.